Impact Biomedical INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
AMEX
Impact BioMedical Inc. has amended its merger agreement with Dr Ashleys Limited, extending the closing deadline to July 1, 2026, and adjusting share considerations for key parties.
AMEX
Impact Biomedical Inc. announced that its stockholders approved the election of eight directors, ratified Grassi & Co. as its independent auditor, and approved executive compensation at its 2025 annual meeting.
AMEX
Impact BioMedical Inc. announced the conversion of Series A Convertible Preferred Stock held by DSS BioHealth Security, Inc. into 60,496,041 shares of common stock.
AMEX
Impact BioMedical Inc. has settled an outstanding $12 million debt with DSS, Inc. by issuing 31.9 million shares of common stock.
AMEX
Impact BioMedical Inc. and Dr Ashleys Limited have entered into a Merger and Share Exchange Agreement, which will result in a reverse merger forming a new publicly traded entity, Dr Ashleys Limited, on the NYSE American, aiming to accelerate the market reach of Impact BioMedical's innovative pharmaceutical patents.
AMEX
Impact BioMedical Inc. reports that DSS, Inc. has withdrawn from the Debt Conversion Agreement due to current market conditions, meaning no shares were issued.
AMEX
Impact BioMedical Inc. settles a portion of its debt with DSS, Inc. by issuing common stock.
AMEX
Impact Biomedical Inc. announces the appointment of Mr. Chan Heng Fai Ambrose, a seasoned financial expert, to its Board of Directors, effective March 11, 2025.
AMEX
Impact Biomedical Inc. announced the release of an investor presentation on January 29, 2025, with no obligation to update the information.
AMEX
Impact Biomedical Inc. released an investor presentation on November 4, 2024, outlining company information.
AMEX
Impact BioMedical Inc. has entered into a new three-year employment agreement with CEO Frank D. Heuszel, outlining his compensation and terms of employment.
AMEX
Impact BioMedical Inc. successfully completed its initial public offering, raising approximately $3.76 million after expenses.
AMEX
8-K: Impact Biomedical Appoints Jason T. Grady to Board Following Resignation of Heng Fai Ambrose Chan
Impact Biomedical Inc. announces the resignation of Heng Fai Ambrose Chan from its Board of Directors and the appointment of Jason T. Grady as a new director, effective June 6, 2024.
AMEX
Impact BioMedical, Inc. has amended its revolving promissory note with DSS, Inc., extending the maturity date to September 30, 2030, and increasing the principal balance to $12,859,328.60.